CLOs on the Move

Virtual Radiologic Corporation

www.vrad.com

 
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.vrad.com
  • 11995 Singletree Ln Ste 500
    Eden Prairie, MN USA 55344
  • Phone: 952.595.1100

Executives

Name Title Contact Details
Maureen Carlson
 Assistant General Counsel Profile
Maureen Carlson
 Associate General Counsel Profile

Similar Companies

Seventh Wave

Seventh Wave is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.

AmbioPharm

AmbioPharm is a Beech Island, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GTx, Inc.

GTx, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.